# Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

> **NCT05549947** · PHASE2 · COMPLETED · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 158 (actual)

## Conditions studied

- Moderate to Severe Atopic Dermatitis

## Interventions

- **DRUG:** SHR-1819
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05549947
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-08
- **Primary completion:** 2023-09-15
- **Final completion:** 2023-11-23
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05549947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05549947, "Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05549947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*